Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 19 2020 - 7:30AM
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage
pharmaceutical company focused on developing next generation oral
and IV antibiotics to treat infections caused by multi-drug
resistant pathogens in both community and hospital settings, today
announced its participation at the 9th Annual
SVB Leerink Global Healthcare Conference. The
conference will be held from February 25th – February 27th in New
York City. Corey Fishman, Chief Executive Officer, is scheduled to
present an overview of the company on Wednesday, February 26, 2020
at 2:00 p.m. ET.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical
company dedicated to developing differentiated anti-infectives
aimed at combatting the global crisis of multi-drug resistant
pathogens to significantly improve the lives of people affected by
serious and life-threatening diseases around the world. Iterum
Therapeutics is advancing its first compound, sulopenem, a novel
penem anti- infective compound, in Phase 3 clinical development
with oral and IV formulations. Sulopenem has demonstrated potent in
vitro activity against a wide variety of gram-negative,
gram-positive and anaerobic bacteria resistant to other
antibiotics. Iterum Therapeutics has received Qualified Infectious
Disease Product (QIDP) and Fast Track designations for its oral and
IV formulations of sulopenem in seven indications. For more
information, please visit http://www.iterumtx.com.
Forward-looking Statements
This press release may contain forward-looking statements. These
forward-looking statements include, without limitation, statements
regarding the development, therapeutic and market potential of
sulopenem. In some cases, forward-looking statements can be
identified by words such as “may,” “believes,” “intends,” “seeks,”
“anticipates,” “plans,” “estimates,” “expects,” “should,”
“assumes,” “continues,” “could,” “will,” “future,” “potential” or
the negative of these or similar terms and phrases. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause Iterum Therapeutics’ actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward- looking statements. Forward-looking statements include
all matters that are not historical facts. Actual future results
may be materially different from what is expected due to factors
largely outside Iterum Therapeutics’ control, including the
uncertainties inherent in the conduct of clinical trials, clinical
trial patient enrollment, availability and timing of data from
clinical trials, changes in regulatory requirements or decisions of
regulatory authorities, the actions of third-party clinical
research organizations, suppliers and manufacturers,
commercialization plans and timelines, if approved, and other
factors discussed under the caption “Risk Factors” in its most
recently filed Quarterly Report on Form 10-Q, and other documents
filed with the SEC from time to time. Forward- looking statements
represent Iterum Therapeutics’ beliefs and assumptions only as of
the date of this press release. Except as required by law, Iterum
Therapeutics assumes no obligation to update these forward-looking
statements publicly, or to update the reasons actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
Investor Contact:
Judy MatthewsChief Financial
Officer312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Sep 2023 to Sep 2024